Gina Battaglia, PhD

Edward B. Garon, MD, discusses the role of EGFR-targeted therapies in the treatment landscape of NSCLC.

Adoptive immunotherapy has shown promising outcomes in early-stage trials for many cancers, but successful approaches in head and neck cancers will require addressing several challenges that are inherent in many solid tumors, such as creating the right homing mechanisms, achieving adequate T-cell infiltration into the tumor, and finding an antigen that will not produce off-tumor effects.

Reactivation of the tumor suppressor gene adenomatous polyposis coli (Apc) reverted colorectal cancer cells back to normal intestinal tissue in mice, according to a recent preclinical study.

On February 13, 2015, the FDA approved lenvatinib for treatment of locally recurrent or metastatic differentiated thyroid cancer that is refractory to radioactive iodine therapy.

According to a recent descriptive analysis of the VA Corporate Data Warehouse, veterans who reported Agent Orange exposure had higher rates of thyroid cancer compared to the overall national VA health care patient population.

Patients with a history of breast cancer have a higher risk of developing thyroid cancer than do the general population, particularly if they receive adjuvant radiation therapy.